The Alzheimer’s Disease Bio-Marker Panel is a blood-based biomarker test that assesses plasma p-tau217 and β-Amyloid 1-42, integrating these two pathological signals into a p-tau217/β-Amyloid 1-42 plasma ratio. Alzheimer’s disease is a biological process involving amyloid and tau pathology, while cognitive symptoms alone may not always reveal the underlying pathology. The panel provides a proactive, biology-driven approach to Alzheimer’s disease assessment, bringing biological evidence closer to clinical decision-making.
| Parameter | Details | |
|---|---|---|
| Biomarkers Analysed | p-tau217 & β-Amyloid 1-42 | |
| Integrated Measure | p-tau217/β-Amyloid 1-42 Plasma Ratio | |
| Clinical Utility | Biology-focused assessment of Alzheimer’s disease | |
| Sample Type | EDTA Plasma | |
| Methodology | CLIA |
Test Code: MGR1831
TAT: 4 working Days
Looks beyond cognitive symptoms to assess biological signals associated with Alzheimer’s disease.
Assesses both amyloid and tau signals.
Integrates the two biomarkers into one plasma signal.
Please share your details to get
in touch with our experts.
